XML 55 R44.htm IDEA: XBRL DOCUMENT
v3.24.3

REVENUE Disaggregated Revenue Table (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended |
--- | --- | --- | ---
Sep. 30, 2024 | Sep. 30, 2023 | Sep. 30, 2024 | Sep. 30, 2023 | Dec. 31, 2023
Disaggregation of Revenue [Line Items] |  |  |  |  |
Accounts Receivable, Allowance for Credit Loss | $ 38.9 |  | $ 38.9 |  | $ 32.7
Unbilled Services, Allowance for Credit Loss | 1.6 |  | 1.6 |  | 7.5
Note Receivable, Allowance for Credit Loss | 0.7 |  | 0.7 |  | 0.7
Allowance for Credit Loss | 41.2 |  | 41.2 |  | 40.9
Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings |  |  | 7.7 |  |
Allowance for Credit Loss, Write Off |  |  | 7.4 |  |
Deferred Revenue, Revenue Recognized | 20.2 | $ 6.3 | 98.0 | $ 79.1 |
Contract with Customer, Asset, before Allowance for Credit Loss | 167.9 |  | 167.9 |  | 192.9
Contract with Customer, Liability | 403.1 |  | 403.1 |  | 421.7
Unbilled Contracts Receivable | $ 166.3 |  | $ 166.3 |  | 185.4
Percent of Revenue Contributed | 100.00% | 100.00% | 100.00% | 100.00% |
Revenues | $ 3,282.0 | $ 3,056.8 | $ 9,679.5 | $ 9,128.3 |
Accounts Receivable, after Allowance for Credit Loss, Current | 2,058.5 |  | 2,058.5 |  | 1,913.3
Allowance for Credit Loss, Receivable, Other, Current | (1.6) |  | (1.6) |  | (7.5)
Contract with Customer, Asset, after Allowance for Credit Loss, Current | $ 166.3 |  | $ 166.3 |  | 185.4
Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 9.00% | 9.00% | 9.00% | 9.00% |
North America |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 87.00% | 87.00% | 87.00% | 87.00% |
Other countries [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 4.00% | 4.00% | 4.00% | 4.00% |
UNITED STATES |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 83.40% | 83.40% | 83.60% | 83.80% |
Revenues | $ 2,738.4 | $ 2,550.6 | $ 8,091.8 | $ 7,645.0 |
Medicare and Medicaid [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 8.00% | 8.00% | 8.00% | 8.00% |
LabCorp Diagnostics [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 78.00% | 77.00% | 78.00% | 77.00% |
LabCorp Diagnostics [Member] | Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 0.00% | 0.00% | 0.00% | 0.00% |
LabCorp Diagnostics [Member] | North America |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 78.00% | 77.00% | 78.00% | 77.00% |
LabCorp Diagnostics [Member] | Other countries [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 0.00% | 0.00% | 0.00% | 0.00% |
LabCorp Diagnostics [Member] | Client [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 24.00% | 24.00% | 24.00% | 24.00% |
LabCorp Diagnostics [Member] | Client [Member] | Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 0.00% | 0.00% | 0.00% | 0.00% |
LabCorp Diagnostics [Member] | Client [Member] | North America |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 24.00% | 24.00% | 24.00% | 24.00% |
LabCorp Diagnostics [Member] | Client [Member] | Other countries [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 0.00% | 0.00% | 0.00% | 0.00% |
LabCorp Diagnostics [Member] | Self-Pay [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 10.00% | 9.00% | 10.00% | 9.00% |
LabCorp Diagnostics [Member] | Self-Pay [Member] | Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 0.00% | 0.00% | 0.00% | 0.00% |
LabCorp Diagnostics [Member] | Self-Pay [Member] | North America |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 10.00% | 9.00% | 10.00% | 9.00% |
LabCorp Diagnostics [Member] | Self-Pay [Member] | Other countries [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 0.00% | 0.00% | 0.00% | 0.00% |
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 0.00% | 0.00% | 0.00% | 0.00% |
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | North America |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 8.00% | 8.00% | 8.00% | 8.00% |
LabCorp Diagnostics [Member] | Medicare and Medicaid [Member] | Other countries [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 0.00% | 0.00% | 0.00% | 0.00% |
LabCorp Diagnostics [Member] | Third party [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 36.00% | 36.00% | 36.00% | 36.00% |
LabCorp Diagnostics [Member] | Third party [Member] | Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 0.00% | 0.00% | 0.00% | 0.00% |
LabCorp Diagnostics [Member] | Third party [Member] | North America |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 36.00% | 36.00% | 36.00% | 36.00% |
LabCorp Diagnostics [Member] | Third party [Member] | Other countries [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 0.00% | 0.00% | 0.00% | 0.00% |
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed |  | 23.00% |  |  |
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed |  | 9.00% |  |  |
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | North America |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed |  | 10.00% |  |  |
Covance Drug Development [Member] | Biopharmaceutical and medical device companies [Member] | Other countries [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed |  | 4.00% |  |  |
Diagnostics |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 78.00% |  |  |  |
Accounts Receivable, before Allowance for Credit Loss | $ 1,323.7 |  | $ 1,323.7 |  | 1,135.2
Drug Development |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 22.00% |  |  |  |
Accounts Receivable, before Allowance for Credit Loss | $ 773.7 |  | $ 773.7 |  | $ 810.8
Drug Development | Biopharmaceutical and medical device companies [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 22.00% |  | 22.00% | 23.00% |
Drug Development | Biopharmaceutical and medical device companies [Member] | Europe [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 9.00% |  | 9.00% | 9.00% |
Drug Development | Biopharmaceutical and medical device companies [Member] | North America |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 9.00% |  | 9.00% | 10.00% |
Drug Development | Biopharmaceutical and medical device companies [Member] | Other countries [Member] |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |
Percent of Revenue Contributed | 4.00% |  | 4.00% | 4.00% |

X
- Definition Allowance for Credit Loss + References No definition available. + Details
Name: | lh_AllowanceforCreditLoss
Namespace Prefix: | lh_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Allowance for Credit Loss, Write Off + References No definition available. + Details
Name: | lh_AllowanceforCreditLossWriteOff
Namespace Prefix: | lh_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Current Expected Credit Losses Opening Balance Sheet Impact on Retained Earnings + References No definition available. + Details
Name: | lh_CurrentExpectedCreditLossesOpeningBalanceSheetImpactonRetainedEarnings
Namespace Prefix: | lh_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Note Receivable, Allowance for Credit Loss + References No definition available. + Details
Name: | lh_NoteReceivableAllowanceforCreditLoss
Namespace Prefix: | lh_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percent of Revenue Contributed + References No definition available. + Details
Name: | lh_PercentofRevenueContributed
Namespace Prefix: | lh_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Unbilled Services, Allowance for Credit Loss + References No definition available. + Details
Name: | lh_UnbilledServicesAllowanceforCreditLoss
Namespace Prefix: | lh_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsReceivableGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of allowance for credit loss on accounts receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details
Name: | us-gaap_AllowanceForDoubtfulAccountsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of allowance for credit loss on receivable, classified as other and current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7A Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3 + Details
Name: | us-gaap_ContractWithCustomerAssetGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerAssetNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously reported as deferred or unearned revenue. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueRevenueRecognized1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-2 + Details
Name: | us-gaap_UnbilledContractsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=lh_OthercountriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerSalesChannelAxis=lh_MedicareandMedicaidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=lh_LabCorpDiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerSalesChannelAxis=lh_ClientMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SelfPayMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerSalesChannelAxis=lh_ThirdpartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=lh_CovanceDrugDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerSalesChannelAxis=lh_BiopharmaceuticalandmedicaldevicecompaniesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=lh_DiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=lh_DrugDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |